Keyphrases
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Trastuzumab
82%
Neratinib
70%
Breast Cancer
61%
Metastatic Breast Cancer
54%
HER2 mutation
38%
Tumor
33%
HER2-positive Breast Cancer
32%
Circulating Tumor DNA (ctDNA)
29%
Basket Study
29%
T-DM1
28%
Paclitaxel
28%
Kinase Domain
28%
Pertuzumab
28%
HER2-positive
26%
Somatic mutation
26%
Activating mutation
25%
Epidermal Growth Factor Receptor
24%
Trastuzumab Emtansine
23%
ErbB2
22%
Genome Sequencing
21%
Receptor Tyrosine Kinase
19%
Phosphorylation
19%
Genetic Modification
19%
Genomic Characterization
19%
HER2-targeted Therapy
18%
HER3
18%
HER4
18%
Her2neu
17%
Ceramide
17%
Adjuvant Trastuzumab
17%
Confidence Interval
16%
Diarrhea
15%
Estrogen Receptor-positive Breast Cancer
15%
Cancer Genome Sequencing
14%
Clinical Trials
14%
Targeted Therapy
13%
C-terminal Tail
13%
PIK3CA
13%
Breast Cancer Subtypes
13%
Tyrosine Kinase
12%
Loperamide
12%
Capecitabine
12%
HER2-negative Breast Cancer
12%
Induced Apoptosis
12%
Fulvestrant
11%
Phosphoproteomics
11%
Objective Response Rate
11%
HER2 Amplification
11%
EGF Receptor
11%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
82%
Kinase
59%
Phosphotransferase
59%
Receptor Tyrosine Kinase
46%
Genomics
42%
Somatic Mutation
30%
Clinical Trial
30%
C-Terminus
27%
Neratinib
25%
Trastuzumab
25%
Tyrosine Kinase
21%
Estrogen Receptor
21%
Carcinogenesis
18%
Phosphoproteomics
17%
Cancer Genome Sequencing
15%
Gene Amplification
15%
Tyrosine Kinase Inhibitor
14%
Tumor Suppressor Protein
14%
Exome Sequencing
14%
ErbB
14%
Genome Sequencing
13%
Conformation
12%
Lapatinib
11%
Oncogene
11%
Drug Resistance
11%
Ceramide
11%
Programmed Cell Death
11%
MAP3K1
10%
KRAS
10%
Signaling Protein
9%
Aromatase Inhibitor
9%
Colon
9%
Indel
9%
Enzyme
8%
Messenger RNA
8%
Point Mutation
8%
Dimerization
7%
Autophosphorylation
7%
Signal Transduction
7%
Gene Interaction
7%
GATA3
7%
Transcription
7%
Quantitative Proteomics
7%
RNA
7%
Transgenic Mouse
7%
Mutation Rate
7%
Missense Mutation
7%
Tyrosine
7%
Loss of Function Mutation
6%
Dynamics
6%
Medicine and Dentistry
Breast Cancer
89%
Trastuzumab
61%
Metastatic Breast Cancer
43%
Neratinib
37%
Neoplasm
35%
Clinical Trial
32%
Targeted Therapy
29%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
25%
Circulating Tumor DNA
24%
Pertuzumab
20%
Epidermal Growth Factor Receptor 2
19%
Epidermal Growth Factor Receptor
19%
Estrogen Receptor Positive Breast Cancer
17%
Adverse Event
17%
Somatic Mutation
16%
Gamma Urogastrone
15%
Malignant Neoplasm
15%
Capecitabine
12%
Recurrent Disease
12%
Tyrosine-Kinase Inhibitor
12%
Biological Marker
12%
Triple Negative Breast Cancer
12%
Paclitaxel
11%
Zirconium 89
11%
Trastuzumab Emtansine
11%
Carcinogenesis
11%
Progression Free Survival
10%
Cancer
10%
Arm
10%
DNA Sequence
10%
Hormone Therapy
10%
Diseases
10%
Adjuvant Therapy
9%
Lapatinib
8%
Gene Amplification
8%
Aromatase Inhibitor
8%
Genome Sequencing
8%
Drug Resistance
7%
Solid Malignant Neoplasm
7%
Metastatic Colorectal Cancer
7%
Disease Free Survival
7%
Molecular Profiling
7%
Lobular Carcinoma
6%
Palbociclib
6%
Colorectal Carcinoma
6%
Docetaxel
6%
Carboplatin
6%
Randomized Controlled Trial
6%
Positron Emission Tomography-Computed Tomography
6%
Cancer Therapy
6%